NASDAQ$IMNM
Immunome Inc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Immunome reported financial results for the third quarter ended September 30, 2022.
Immunome reported its Q3 2022 financial results and provided a corporate update, focusing on the clinical trial for IMM-BCP-01 and the expansion of its oncology portfolio.
- Completing clinical trial for IMM-BCP-01, its COVID-19 antibody program.
- Continuing to expand oncology portfolio including planned submission of the IND for IMM-ONC-01 by mid 2023.
- Monitoring the evolution of multiple new variants of SARS-CoV-2, including BA.4.6, BQ.1, BQ.1.1 and BF.7.
- Anticipating obtaining topline safety and PK data by the end of the year and look forward to announcing those results in the beginning of 2023.
Headline financials
Revenue & EPS history
Immunome · Revenue · Quarterly
$6K
Forward guidance
Immunome is focused on advancing its platform and programs, executing its regulatory, research, clinical and strategic plans, and achieving anticipated upcoming milestones.
Tailwinds
- Advancement of its platform and programs
- Execution of its regulatory plans
- Execution of research plans
- Execution of clinical plans
- Execution of strategic plans
Headwinds
- Impact of the COVID-19 pandemic on Immunome’s business
- Research and development data are subject to differing interpretations and assessments
- Ability to execute on its strategy, including with respect to its R&D efforts, IND submissions and other regulatory filings
- Effectiveness of Immunome’s product candidates, including the possibility that further preclinical data and any clinical trial data may be inconsistent with the data used for advancing the product candidates and that further variants of concern could emerge
- Ability to fund operations and raise capital
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2022
+0.8%
Avg return
Earnings day
-2.4%
Avg return
5 days after
+0.6%
Avg return
30 days after
32%
7 / 22 earnings
Positive
+24.1%
Q4 2021
Best reaction
-10.8%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -1.3% | -9.1% | -20.0% | |
| Q4 2025 | +4.7% | -1.0% | +1.4% | |
| Q3 2025 | -5.0% | +2.5% | +12.3% | |
| Q1 2025 | +1.1% | -1.0% | +15.0% | |
| Q4 2024 | -4.0% | -18.9% | -7.7% | |
| Q3 2024 | -10.8% | -24.5% | +0.7% | |
| Q2 2024 | +4.7% | +4.7% | +11.9% | |
| Q1 2024 | -1.3% | -6.2% | -3.2% | |
| Q4 2023 | -2.3% | -16.2% | -46.2% | |
| Q3 2023 | -8.1% | -8.9% | -12.2% | |
| Q2 2023 | -1.9% | -0.8% | +3.9% | |
| Q1 2023 | +2.3% | +11.9% | -6.2% | |
| Q4 2022 | +20.8% | +18.9% | +2.3% | |
| Q3 2022 | +0.0% | -27.6% | -8.5% | |
| Q2 2022 | +19.3% | +13.6% | +24.7% | |
| Q1 2022 | -2.6% | +19.6% | +46.5% | |
| Q4 2021 | +24.1% | +20.1% | -26.3% | |
| Q3 2021 | -1.0% | -5.1% | -9.3% | |
| Q2 2021 | -3.2% | -11.9% | +51.2% | |
| Q1 2021 | -10.7% | -3.0% | -2.9% | |
| Q4 2020 | -1.0% | -4.3% | -8.3% | |
| Q3 2020 | -5.5% | -6.4% | -6.1% | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro